Dataset Information


Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

ABSTRACT: Many experimental and clinical studies suggest a relationship between enhanced angiotensin II release by the angiotensin-converting enzyme (ACE) and the pathophysiology of atherosclerosis. The atherosclerosis-enhancing effects of angiotensin II are complex and incompletely understood. To identify anti-atherogenic target genes, we performed microarray gene expression profiling of the aorta during atherosclerosis prevention with the ACE inhibitor, captopril. Atherosclerosis-prone apolipoprotein E (apoE)-deficient mice were used as a model to decipher susceptible genes regulated during atherosclerosis prevention with captopril. Microarray gene expression profiling and immunohistology revealed that captopril treatment for 7 months strongly decreased the recruitment of pro-atherogenic immune cells into the aorta. Captopril-mediated inhibition of plaque-infiltrating immune cells involved down-regulation of the C-C chemokine receptor 9 (CCR9). Reduced cell migration correlated with decreased numbers of aorta-resident cells expressing the CCR9-specific chemoattractant factor, chemokine ligand 25 (CCL25). The CCL25-CCR9 axis was pro-atherogenic, because inhibition of CCR9 by RNA interference in hematopoietic progenitors of apoE-deficient mice significantly retarded the development of atherosclerosis. Analysis of coronary artery biopsy specimens of patients with coronary artery atherosclerosis undergoing bypass surgery also showed strong infiltrates of CCR9-positive cells in atherosclerotic lesions. Thus, the C-C chemokine receptor, CCR9, exerts a significant role in atherosclerosis.


PROVIDER: S-EPMC2906340 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2009-12-03 | GSE19286 | GEO
2009-12-14 | E-GEOD-19286 | ArrayExpress
1000-01-01 | S-EPMC3428084 | BioStudies
2011-01-01 | S-EPMC3086928 | BioStudies
2010-01-01 | S-EPMC2945064 | BioStudies
1000-01-01 | S-EPMC3854782 | BioStudies
1000-01-01 | S-EPMC5009347 | BioStudies
2014-01-01 | S-EPMC6249688 | BioStudies
2015-01-01 | S-EPMC4592714 | BioStudies
2017-01-01 | S-EPMC7108029 | BioStudies